The ADC Supply Squeeze: Free Extract
Announced ADC manufacturing capacity and staffed ADC manufacturing capacity are not the same thing. This free extract takes twenty announced expansions from 2022 to May 2026 and tests each one against a single question: can co-located ADC manufacturing hiring be confirmed at that site. The distance between the two is what it measures.
What this report answers
- Is the announced wave of ADC manufacturing capacity actually being staffed?
- Which announced ADC sites are operational and hiring today, and which are dated to the end of the decade?
- How many net-new specialist ADC roles has the reshoring wave announced, and when do they land?
- What does the pay gap between drug developers and contract manufacturers do to the specialist bench?
- How much announced ADC capacity has already been cancelled after the capital was committed?
- How should a sponsor or an investor read a headline ADC capacity number?
~2,875
net-new specialist ADC manufacturing roles the extract counts across the announced reshoring wave, almost all of them dated 2029 and 2030 - ProGen Search analysis, factual cutoff Q2 2026.
Twenty sites
the announced ADC capacity expansions tested one by one for a co-located hiring signal, then sorted into four states by what that signal showed.
What the analysis establishes
The test applied to every announced site
The extract sets out the three steps that sit between a press release and a first commercial batch, then argues only one of them is binding. Every announced expansion is put to a single test: whether matching, co-located ADC manufacturing hiring can be confirmed at the announced location. It states the pass condition and the fail condition before showing any result.
The exhibit: twenty sites, four states
The signature exhibit sorts every tracked expansion into four states defined by hiring signal rather than by capital committed. Each state carries its own site list, its own dollar and headcount totals, and a short note on the pattern the state represents. The extract explains why the four-way split is the part a competitor cannot easily reproduce.
What separates near-term capacity from headline capacity
Two of the four states are characterised in detail: the capacity that is operational now, described by its scale, site type and relationship to existing containment infrastructure, and the capacity carrying the largest capital commitments, described by its announced dates and by where its owners are in fact hiring ADC staff instead.
Capacity that was announced and then withdrawn
A separate state covers announced ADC build-outs that were cancelled or abandoned after capital had been committed, with the charge taken and the stated reason in each case. The extract uses these to make a point about asymmetry: what a builder can reverse in a quarter against what a builder cannot rebuild on the same timetable.
The evidence gap, stated as a gap
One state exists purely for sites whose role-level hiring sits behind authenticated portals or local job boards this analysis could not access. The extract explains why those sites are counted neither as proven nor as empty, gives a primary-sourced counter-example that proves the discipline is warranted, and sets out how a buyer should read all three live states together.
The labour arithmetic and the pay line
The closing pages put four numbers behind the constraint: the specialist roles announced, the slack in the workforce they must come from, the number of manufacturers that can run a complete ADC in one place, and the lead time on one particular regulatory hire. A second page compares employer-disclosed salary bands on each side of the developer and contract-manufacturer line.
How it was built
Every announced ADC capacity expansion from 2022 to May 2026 was taken and tested against one question: can matching, co-located ADC manufacturing hiring be confirmed at the announced location. Sites with confirmed co-located hiring are counted as real and ramping; sites with capacity but no confirmable production hiring at that location are counted as promised, not staffed. Hiring data behind a login or on gated job boards is treated as unconfirmed, not as evidence either way, and is reported in its own state. Salary comparisons use employer-disclosed ranges in USD. This is ProGen Search analysis with a factual cutoff of Q2 2026, and the source notes state the figures are traced to a reconciled evidence base.
Written for ADC developers planning commercial supply, contract manufacturing leadership teams defending a specialist bench, and investors and lenders underwriting announced ADC capacity.
Contents
- The finding
- Method: how each announced site was tested
- Exhibit: co-located hiring signal, twenty sites, four states
- State 1: operational and hiring now
- State 2: announced big, not yet staffed
- State 3: confirmed build, hiring not confirmable
- State 4: announced capacity that evaporated
- The binding constraint
- Retention is the moat
- The read: developers, contract manufacturers, capital allocators
Organisations covered
AbbVie, AstraZeneca, Axplora, BSP Pharmaceuticals, Cerbios-Pharma, Daiichi Sankyo, Eli Lilly, Gilead, Lonza, Lotte Biologics, Merck & Co., MilliporeSigma, Pfizer, Samsung Biologics, Seagen, Shilpa Medicare, Simtra BioPharma Solutions, Veranova, WuXi XDC
The full 12-page briefing is free. Tell us where to send it and it downloads immediately.
The ADC Supply Squeeze
This free document is one exhibit lifted from a paid report. The full report runs the same evidence standard across nine sections and the whole ADC chain, from the demand wave through to the outlook and its leading indicators.
See the full report →